Document is current

Article History

Received: 28 April 2021

Accepted: 11 October 2021

First Online: 18 October 2021

Declarations

:

: This trial was approved by the Alfred Hospital Ethics Committee (Project No. 591/19; approved 25 November 2019).

: Written informed consent was obtained from each participant before any trial-related procedures were performed.

: Written informed consent to have de-identified data submitted for publication was obtained from each participant before any trial-related procedures were performed.

: Dr. Peters is an employee of Canopy Growth Corporation, during which time she has received stock options. She also serves as a consultant to Battelle. Dr. MacNair is an employee of Canopy Growth Corporation, during which time she has received stock options. Ms. Mosesova was an employee of Canopy Growth Corporation, during which time she received stock options. Mr. Land was an employee of Canopy Growth Corporation, during which time he received stock options, and was a prior employee of GW Pharmaceuticals. Ms. Turcotte is an employee of Canopy Growth Corporation, during which time she has received stock options. Dr. Ware is an employee of Canopy Growth Corporation, during which time he has received stock options. Dr. Bonn-Miller is an employee of Canopy Growth Corporation, during which time he has received stock options. He served on the Board of Directors for AusCann Group Holdings Limited, was a prior employee of Zynerba Pharmaceuticals, and has received consulting fees from Tilray Inc. None of the other authors reports a conflict of interest.